Vor Biopharma Inc.
VOR
$2.17
-$0.03-1.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.21% | -15.24% | -12.12% | -9.39% | -4.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.76% | -4.53% | -3.85% | -3.78% | 12.01% |
| Operating Income | -169.76% | 4.53% | 3.85% | 3.78% | -12.01% |
| Income Before Tax | -1,309.41% | 1.36% | 0.81% | 2.64% | -11.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,309.41% | 1.36% | 0.81% | 2.64% | -11.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,309.41% | 1.36% | 0.81% | 2.64% | -11.29% |
| EBIT | -169.76% | 4.53% | 3.85% | 3.78% | -12.01% |
| EBITDA | -173.99% | 4.51% | 3.99% | 4.16% | -12.03% |
| EPS Basic | -685.98% | 15.13% | 3.01% | 12.88% | 14.32% |
| Normalized Basic EPS | -671.87% | 15.12% | 3.00% | 12.87% | 14.32% |
| EPS Diluted | -685.98% | 15.13% | 3.01% | 12.88% | 14.32% |
| Normalized Diluted EPS | -671.87% | 15.12% | 3.00% | 12.87% | 14.32% |
| Average Basic Shares Outstanding | 42.98% | 22.59% | 2.26% | 10.69% | 25.42% |
| Average Diluted Shares Outstanding | 42.98% | 22.59% | 2.26% | 10.69% | 25.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |